Literature DB >> 22056109

Diagnostic performance of initial salivary alpha-amylase activity for acute myocardial infarction in patients with acute chest pain.

Ying-Sheng Shen1, Wei-Lung Chen, Hsin-Yu Chang, Hung-Yi Kuo, Yue-Cune Chang, Hsin Chu.   

Abstract

BACKGROUND: To rule out acute myocardial infarction (AMI) in chest pain patients constitutes a diagnostic challenge to emergency department (ED) physicians. STUDY
OBJECTIVES: To evaluate the diagnostic value of measuring salivary alpha-amylase (sAA) activity for detecting AMI in patients presenting to the ED with acute chest pain.
METHODS: sAA activity was measured in a prospective cohort of 473 consecutive adult patients within 4 h of onset of chest pain. Comparisons were made between patients with a final diagnosis of AMI and those with non-AMI. Univariate analysis and multiple logistic regression model were used to identify independent clinical predictors of AMI.
RESULTS: Initial sAA activity in the AMI group (n = 85; 266 ± 127.6 U/mL) was significantly higher than in the non-AMI group (n = 388; 130 ± 92.8 U/mL, p < 0.001). sAA activity levels were also significantly higher in patients with ST elevation AMI (n = 53) compared to in those with non-ST elevation AMI (n = 32) (300 ± 141.1 vs. 210 ± 74.1 U/mL, p < 0.001). The area under the receiver operating characteristic curve of sAA activity for predicting AMI in patients with acute chest pain was 0.826 (95% confidence interval [CI] 0.782-0.869), with diagnostic odds ratio 10.87 (95% CI 6.16-19.18). With a best cutoff value of 197.7 U/mL, the sAA activity revealed moderate sensitivity and specificity as an independent predictor of AMI (78.8% and 74.5%).
CONCLUSIONS: High initial sAA activity is an independent predictor of AMI in patients presenting to the ED with chest pain.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22056109     DOI: 10.1016/j.jemermed.2011.06.040

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  6 in total

Review 1.  Saliva diagnostics - Current views and directions.

Authors:  Karolina Elżbieta Kaczor-Urbanowicz; Carmen Martin Carreras-Presas; Katri Aro; Michael Tu; Franklin Garcia-Godoy; David Tw Wong
Journal:  Exp Biol Med (Maywood)       Date:  2016-12-08

2.  Correlation of salivary alpha amylase level and adenotonsillar hypertrophy with sleep disordered breathing in pediatric subjects.

Authors:  Chan-Soon Park; Christian Guilleminault; Hong-Jin Park; Jin-Hee Cho; Heung-Ku Lee; Hye-Lim Son; Se-Hwan Hwang
Journal:  J Clin Sleep Med       Date:  2014-05-15       Impact factor: 4.062

3.  Utility of salivary biomarkers for demonstrating acute myocardial infarction.

Authors:  C S Miller; J D Foley; P N Floriano; N Christodoulides; J L Ebersole; C L Campbell; A L Bailey; B G Rose; D F Kinane; M J Novak; J T McDevitt; X Ding; R J Kryscio
Journal:  J Dent Res       Date:  2014-05-30       Impact factor: 6.116

Review 4.  Can Saliva Proteins Be Used to Predict the Onset of Acute Myocardial Infarction among High-Risk Patients?

Authors:  Mohd Aizat Abdul Rahim; Zubaidah Haji Abdul Rahim; Wan Azman Wan Ahmad; Onn Haji Hashim
Journal:  Int J Med Sci       Date:  2015-04-03       Impact factor: 3.738

5.  Translocator Protein Modulation by 4'-Chlorodiazepam and NO Synthase Inhibition Affect Cardiac Oxidative Stress, Cardiometabolic and Inflammatory Markers in Isoprenaline-Induced Rat Myocardial Infarction.

Authors:  Ana Ilic; Dusan Todorovic; Slavica Mutavdzin; Novica Boricic; Biljana Bozic Nedeljkovic; Sanja Stankovic; Tatjana Simic; Predrag Stevanovic; Vera Celic; Dragan Djuric
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

6.  Relevance of cortisol and copeptin blood concentration changes in an experimental pain model.

Authors:  Claudine A Blum; Laëtitia Velly; Christine Brochet; Frédéric Ziegler; Marie-Pierre Tavolacci; Pierre Hausfater; Virginie Eve Lvovschi
Journal:  Sci Rep       Date:  2022-03-19       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.